{
  "main_header": {
    "sid": 1151933,
    "name": "Catalyst Biosciences, Inc.",
    "stock_name": "Catalyst Biosciences, Inc.",
    "full_name": "Catalyst Biosciences, Inc.",
    "name_url": "stocks-analysis/catalyst-biosciences-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "7.90",
    "chg": 0.32,
    "chgp": "4.22%",
    "dir": 1,
    "prev_price": "7.58",
    "mcapval": "747.39",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US14888D2080",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "39.88 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/catalyst-biosciences-inc-1151933-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Catalyst Biosciences, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-catalyst-biosciences-inc-technically-bullish-or-bearish-3547563",
        "imagepath": "",
        "date": "2025-09-20 19:58:17",
        "description": "As of 12 August 2025, the technical trend for Catalyst Biosciences, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly and monthly MACD and KST show mild bullishness. However, Bollinger Bands and OBV suggest bearishness on the monthly timeframe. \n\nIn terms of performance, the stock has significantly underperformed compared to the S&P 500 across all multi-period returns, with a year-to-date decline of 36.45% versus the S&P 500's gain of 12.22%...."
      },
      {
        "title": "Is Catalyst Biosciences, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-catalyst-biosciences-inc-overvalued-or-undervalued-3543897",
        "imagepath": "",
        "date": "2025-09-20 18:31:58",
        "description": "As of 9 May 2025, the valuation grade for Catalyst Biosciences, Inc. has moved from fair to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its high P/E ratio of 94, a Price to Book Value of 10.60, and an EV to EBITDA ratio of 57.11, which are significantly higher than its peers. For instance, Equillium, Inc. has a P/E ratio of -5.54, and OncoCyte Corp. shows a P/E of -2.92, highlighting the relative overvaluation of Catalyst.\n\nThe company's stock has underperformed compared to the S&P 500, with a year-to-date return of -36.45% versus the index's 12.22%, and a staggering 5-year return of -89.36% compared to the S&P's 96.61%. This significant underperformance reinforces the conclusion that Catalyst Biosciences, Inc. is currently overvalued...."
      }
    ],
    "total": 7,
    "sid": "1151933",
    "stock_news_url": "https://www.marketsmojo.com/news/catalyst-biosciences-inc-1151933"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Catalyst Biosciences, Inc. technically bullish or bearish?

2025-09-20 19:58:17

As of 12 August 2025, the technical trend for Catalyst Biosciences, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly and monthly MACD and KST show mild bullishness. However, Bollinger Bands and OBV suggest bearishness on the monthly timeframe. In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all multi-period returns, with a year-to-date decline of 36.45% versus the S&P 500's gain of 12.22%....

Read More

Is Catalyst Biosciences, Inc. overvalued or undervalued?

2025-09-20 18:31:58

As of 9 May 2025, the valuation grade for Catalyst Biosciences, Inc. has moved from fair to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its high P/E ratio of 94, a Price to Book Value of 10.60, and an EV to EBITDA ratio of 57.11, which are significantly higher than its peers. For instance, Equillium, Inc. has a P/E ratio of -5.54, and OncoCyte Corp. shows a P/E of -2.92, highlighting the relative overvaluation of Catalyst. The company's stock has underperformed compared to the S&P 500, with a year-to-date return of -36.45% versus the index's 12.22%, and a staggering 5-year return of -89.36% compared to the S&P's 96.61%. This significant underperformance reinforces the conclusion that Catalyst Biosciences, Inc. is currently overvalued....

Read More

View All News